[1] Cegrell L. Insulin biosynthesis, storage and secretion. 12. Biogenic mono-amines in the endocrine pancreas of guinea pigs[J]. Lakartidningen, 1968, 11;65(37):3616-3617.[2] Baines A D, Craan A, Chan W, et al. Tubular secretion and metabolism of dopamine, norepinephrine, methoxytyramine and normetanephrine by the rat kidney[J]. Journal of Pharmacology & Experimental Therapeutics, 1979, 208(1):144-147.[3] Mezey E, Eisenhofer G, Hansson S, et al. Non-neuronal dopamine in the gastrointestinal system[J]. Clinical & Experimental Pharmacology & Physiology Supplement, 1999, 26(4):S14-22.[4] Glavin G B, Hall A M. Central and peripheral dopamine D 1/DA 1 receptor modulation of gastric secretion and experimental gastric mucosal injury[J]. General Pharmacology, 1995, 26(6):1277-1279.[5] Zhang X, Guo H, Xu J, et al. Dopamine receptor D1 mediates the inhibition of dopamine on the distal colonic motility[J]. Translational Research, 2012, 159(5):407-414.[6] Kullmann R, Breull W R, Reinsberg J, et al. Dopamine produces vasodilation in specific regions and layers of the rabbit gastrointestinal tract[J]. Life Sciences, 1983, 32(18):2115-2122.[7] Zheng L F, Song J, Fan R F, et al. The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra[J]. Acta Physiologica, 2014, 211(2):434-446.[8] Morley J F, Pawlowski S M, Kesari A, et al. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism[J]. Parkinsonism & Related Disorders, 2014, 20(7):738-742.[9] Song J, Zheng L, Zhang X, et al. Upregulation of β1 -adrenoceptors is involved in the formation of gastric dysmotility in the 6-hydroxydopamine rat model of Parkinson's disease[J]. Translational Research, 2014, 164(1):22-31.[10] Gan J, Zhou M, Chen W, et al. Non-motor symptoms in Chinese Parkinson's disease patients[J]. Journal of Clinical Neuroscience, 2014, 21(5):751-754.[11] Wang Q, Ji T, Zheng L F, et al. Cellular localization of dopamine receptors in the gastric mucosa of rats[J]. Biochemical & Biophysical Research Communications, 2012, 417(1):197-203.[12] Goto Y, Berelowitz M, Frohman L A. Effect of catecholamines on somatostatin secretion by isolated perfused rat stomach[J]. Am J Physiol, 1981, 240(3):E274-E278.[13] Tani S, Tanaka T. Direct inhibition of pepsinogen secretion from rat gastric chief cells by somatostatin[J]. Chemical & Pharmaceutical Bulletin, 1990, 38(8):2246-2248.[14] Bloom S R, Ralphs D N, Besser G M, et al. Proceedings: Effect of somatostatin on motilin levels and gastric emptying[J]. Gut, 1975, 16(10):834-834.[15] Siler T M, VandenBerg G, Yen S S, et al. Inhibition of growth hormone release in humans by somatostatin[J]. Journal of Clinical Endocrinology & Metabolism, 1973, 37(4):632-634.[16] Zaki M, Harrington L, McCuen R,et al. Somatostatin receptor subtype 2 mediates inhibition of gastrin and histamine secretion from human, dog, and rat antrum[J]. Gastroenterology, 1996, 111(4):919-924.[17] Corleto V D, Weber H C, Jensen R T. Expression of somatostatin receptor subtypes on guinea pig gastric and colonic smooth muscle cells[J]. American Journal of Physiology, 1999, 277(1):G235-44.[18] Gu Z F, Corleto V D, Mantey S A, et al. Somatostatin receptor subtype 3 mediates the inhibitory action of somatostatin on gastric smooth muscle cells[J]. American Journal of Physiology, 1995, 268(5):739-G748.[19] Hakanson R.Formation of amines in the gastric mucosa of the rat[J]. Nature, 1965, 20;208(5012):793-4.[20] Sikiric P, Rotkvic I, Mise S, et al. Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine[J]. Digestive Diseasess & ssciences, 1991, 36(7):905-910.[21] Glavin G B, Szabo S. Dopamine in gastrointestinal disease[J]. Digestive Diseases & Sciences, 1990, 35(9):1153-1161.[22] 邓小英, 郑芝田, 叶嗣懋,等. 多巴胺受体在大鼠胃和十二指肠的定位及表达[J]. 中华医学杂志, 1997, 77(2):103-105. |